Summary
Gilead Sciences, Inc. (GILD) filed an 8-K on October 30, 2003, reporting a significant amendment to its stockholder rights plan. The company's Board of Directors approved changes to the rights agreement, primarily increasing the exercise price of existing rights to $400 from $100 and extending the expiration date to October 27, 2013. This amendment is designed to provide continued protection against hostile takeovers while allowing flexibility for board-approved business combinations. The primary purpose of this action is to safeguard shareholder value by deterring unsolicited acquisition attempts that may not be in the best interest of the company and its stockholders. The revised rights plan is structured to dilute the stake of any entity attempting an unapproved acquisition, thereby encouraging potential acquirers to negotiate directly with the board. This move is standard practice for companies seeking to maintain strategic control and ensure that any future changes in ownership are conducted on favorable terms.
Key Highlights
- 1Gilead Sciences amended its stockholder rights plan (also known as a 'poison pill').
- 2The exercise price of the rights was increased from $100 to $400 per one four-hundredth of a share of Series A Junior Participating Preferred Stock.
- 3The expiration date of the rights was extended to October 27, 2013.
- 4The amendments are intended to provide anti-takeover protection against hostile acquisitions.
- 5The rights are designed to cause substantial dilution to any entity attempting an unapproved acquisition.
- 6The company retains the ability to redeem the rights or amend them to permit board-approved mergers or business combinations.
- 7The rights will continue to trade with the company's common stock unless triggered by specific events.